| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |